These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1076 related items for PubMed ID: 18562504

  • 1. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 2. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalbán X.
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [Abstract] [Full Text] [Related]

  • 3. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G, COGIMUS Study Group.
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [Abstract] [Full Text] [Related]

  • 4. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 5. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [Abstract] [Full Text] [Related]

  • 6. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
    Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelli V, Comi G, Filippi M.
    Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
    [Abstract] [Full Text] [Related]

  • 7. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 8. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J, Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X.
    Ann Neurol; 2002 Oct; 52(4):400-6. PubMed ID: 12325067
    [Abstract] [Full Text] [Related]

  • 9. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
    Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, Gallo P, Filippi M.
    Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
    [Abstract] [Full Text] [Related]

  • 10. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X.
    Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 14. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 15. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.
    Annunziata P, Giorgio A, De Santi L, Zipoli V, Portaccio E, Amato MP, Clerici R, Scarpini E, Moscato G, Iudice A, Vacca G, Orefice G, Morra VB, Maimone D.
    J Neurol Sci; 2006 May 15; 244(1-2):97-102. PubMed ID: 16473370
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 15; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.